Immunology

Patients with rheumatoid arthritis and obesity exhibited worse scores for subjective measures like pain and fatigue compared with those without obesity.

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.

Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.

Among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), intense pain symptoms were associated with poor sleep, fibromyalgia, depression, and sleep apnea.

A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.

Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.

Areas of focus in the annual report included health system utilization and recovery from the pandemic, patterns of medicine use, drug pricing, and patient out-of-pocket costs.

Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.

Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.

Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.

Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.

Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.

The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

A history of depression was the most predictive factor for developing persistent joint pain among patients with psoriatic arthritis.

Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.

A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.

Research presented at the American Academy of Dermatology Annual Meeting 2024 explored the impact of social determinants of health on hidradenitis suppurativa severity.

While dietary interventions do not significantly change the body composition of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA), they can reduce the risk of cardiovascular disease (CVD).

Despite its impact on patient quality of life, hidradenitis suppurativa (HS) remains underdiagnosed and undertreated; authors outline what's being discovered within the treatment landscape.

A recent study identified a significant association between psoriasis and inflammatory bowel disease. This link also applied to IBD subtypes: Crohn disease and ulcerative colitis.

Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.

Findings reveal an increased risk of psoriatic arthritis (PsA) among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).